NLRP3 and COVID-19: Taken together, there is encouraging evidence for the proposition that targeting the immune cascade and molecular signaling pertaining to NLRP3-inflammasome-mediated inflammation and hypercoagulability may provide fresher avenue into a therapeutic strategy for brain repair following COVID-19 ischemic stroke and future post-acute and/or long COVID-19 syndrome.